Nasdaq
$0.4900▼ 2.85%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $58.5MShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 5d agoRegular26.10.20 22:378-KKey event#●●●#●●●
ONCOLYTICS BIOTECH INC
Oncolytics Biotech announced the presentation of a trial-in-progress abstract for its REO 033 study of pelareorep in metastatic colorectal cancer at the ESMO Congress 2026. The study aims to validate efficacy signals observed in the previous REO 022 trial and generate controlled clinical data to support future regulatory registration.…more
$0.4900-2.85%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Regular26.10.14 22:338-KKey event
ONCOLYTICS BIOTECH INC
Oncolytics Biotech expects to receive the final grant payment from PanCAN following the completion of GOBLET study Cohort 5 activities. The company plans to report final results for Cohort 4 in Q4 2026 and initial results for Cohort 5 in the first half of 2027.…more
$0.4900-2.85%vs prev closeView filingShare - 10.13Pre-market26.10.13 21:108-KKey event
ONCOLYTICS BIOTECH INC
Oncolytics Biotech has announced an expansion of its intellectual property portfolio for its cancer immunotherapy, pelareorep, aiming to extend patent protection into the late 2040s. The company has secured new method-of-use patents in several countries and is currently pursuing U.S. patent issuance and a new composition-of-matter patent for a next-generation version of the drug.…more
$0.4900-2.85%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoRegular26.10.20 22:35#●●●#●●●#●●●
Oncolytics Biotech Presents Pelareorep Colorectal Cancer Trial Update at ESMO…more
Oncolytics Biotech presented a trial-in-progress abstract for its colorectal cancer candidate, pelareorep, at the ESMO Congress. While the company aims to validate efficacy signals observed in previous studies, the trial is still ongoing and requires further clinical data.…more
$0.4900-2.85%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Regular26.10.14 22:30
●●●●●●●● ●●●●● ●●●●●●
Oncolytics Biotech announced the successful completion of Cohort 5 in its GOBLET study and the receipt of the final PanCAN grant payment. The company plans to use the clinical data to refine its development strategy for pelareorep in gastrointestinal cancers.…more
$0.4900-2.85%vs prev close - 10.12After-hours26.10.13 05:05
●●●●●●●● ●●●●● ●●●●●●
Oncolytics Biotech is expanding its intellectual property portfolio for its cancer immunotherapy candidate, pelareorep, aiming to secure patent protection through the late 2040s. As these patents are currently in the application or pending stage, this update is considered a neutral development regarding immediate financial or clinical impact.…more
$0.4900-2.85%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report